Jennifer Brogdon

USPTO Granted Patents = 37 (Patent Applications = 22)

CIPO Patents = 3 (Patent Applications = 15)

EPO Patents = 15 (Patent Applications = 36)

Average Co-Inventor Count = 8.9

ph-index = 8

Forward Citations = 405(Granted Patents)

Location History:

Cambridge, MA (US) (2016 - 2023)
Sudbury, MA (US) (2016 - 2024)

Company Filing History:

University of Pennsylvania

patents

3 out of 1,863

University of Pittsburgh

patents

4. 2 out of 1,209

Dana-farber-cancer Institute Inc.

Intellia Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),

2. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),

3. 12214037 - Treatment of cancer using humanized anti-BCMA chimeric antigen receptor (2025-02-04),

4. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

5. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),

6. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),

7. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),

8. 11851659 - Compositions and methods for immunooncology (2023-12-26),

9. 11591404 - Treatment of cancer using a CD123 chimeric antigen receptor (2023-02-28),

10. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),

11. 11542488 - Sortase synthesized chimeric antigen receptors (2023-01-03),

12. 11459390 - Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor (2022-10-04),

13. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),

14. 11149076 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2021-10-19),

15. 11084880 - Anti-BCMA chimeric antigen receptor (2021-08-10),

Title: Jennifer Brogdon: Pioneering Innovations in the Field of Biotechnology

Introduction:

Jennifer Brogdon, a visionary inventor hailing from Sudbury, MA, has made a significant mark in the world of inventors with her relentless pursuit of innovation and remarkable creativity. Her work continues to inspire and shape the future of technology, particularly in the realm of biotechnology.

Latest Patents:

Jennifer Brogdon's latest patents showcase her groundbreaking contributions to the field of medicine and biotechnology. One of her notable inventions is the development of nucleic acid molecules encoding chimeric antigen receptors with a CD20 binding domain. These compositions and methods have paved the way for novel approaches in treating diseases associated with CD20 or CD22 expression, such as certain types of cancer.

Another significant patent by Jennifer Brogdon focuses on a method for treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain. This innovative approach highlights her commitment to advancing therapeutic interventions in the fight against cancer and other related diseases.

Career Highlights:

Throughout her illustrious career, Jennifer Brogdon has made invaluable contributions at esteemed organizations such as Novartis AG and the University of Pennsylvania. Her innovative research and dedicated work have been instrumental in shaping the landscape of biotechnology and medical advancements.

Collaborations:

Jennifer Brogdon's collaborative spirit is evident through her work with esteemed colleagues such as Andreas Loew and Carl H June. These partnerships have facilitated the exchange of ideas, leading to groundbreaking discoveries and advancements in the field of biotechnology.

Conclusion:

In conclusion, Jennifer Brogdon's unwavering dedication to innovation and her pioneering spirit have solidified her position as a standout figure in the world of inventors. Her remarkable contributions continue to push the boundaries of technology and inspire future generations of inventors.

This text is generated by artificial intelligence and may not be accurate.